ALS Worldwide welcomes any questions or comments you might have.  We provide free, personalized and confidential support services to anyone in the ALS community—whether you are a patient or a loved one, friend, health care professional or caregiver of someone diagnosed.

Get help now! Fill out the Online Profile Form or if you would prefer to talk with someone by email or phone first, please contact us at [email protected] or 1-608-663-0920.

For all other inquiries, please use the email form to the right and we will respond promptly to your request.Thank you.

ALS Worldwide
5808 Dawley Drive
Fitchburg, WI 53711‑7209

ALS Worldwide
Sorted by category: Medications | View All
October 24, 2017

On The Treatment Trail for ALS

The esteemed journal Nature published the following article on October 19, 2017 about ALS and ALS Worldwide.

July 10, 2017

More results are in! Edavone shown to provide greater benefits to ALS patients after one year

Data from the open-label extension trial of Edaravone (Radicava) in patients with ALS demonstrated the drug continued to provide benefits after 48 weeks of treatment.

May 15, 2017

ALS Worldwide Pioneered and Continues the Use of Neudexta

New articles about the benefits of this drug continue to appear, yet ALS Worldwide has been endorsing generic Neudexta for ten years!

May 06, 2017

FDA Approval of Edaravone

On May 5, 2017, FDA authorization was granted to Mitsubishi Tanabe Pharma America, Inc. to manufacture and distribute this important medication. *View ALS Worldwide Press Release

April 26, 2017

Are You Facing High-Cost Treatment Options For ALS?

ALS Worldwide endorses drugs that we feel are both worth the cost and beneficial. The newest trial pharmaceuticals we endorse are Edaravone and Masitinib.

March 27, 2017

Masitinib & Edaravone: Two Proven ALS Drugs Await Simultaneous FDA Approval

Masitinib And Edaravone: Two Proven ALS Drugs Await Simultaneous FDA Approval.